Webster Equity Partners agrees to acquire Lifecore Biomedical
The pending take-private offers $6.28 per share in cash plus a contingent value right tied to milestones.
- Target
- Lifecore Biomedical
- Buyer
- Webster Equity Partners
- Sponsor
- Webster Equity Partners
- Value
- up to $663.7 million
Lifecore Biomedical has entered a definitive agreement to be acquired by an affiliate of Webster Equity Partners. Shareholders would receive $6.28 per share in cash at closing plus a non-tradable contingent value right tied to specified milestones.
The transaction remains subject to shareholder approval and other closing conditions. Lifecore is a contract development and manufacturing organization focused on injectable drug products.
The agreement includes a 30-day go-shop period during which Lifecore may consider alternative proposals. The companies announced the agreement.
Background
- Business
- Contract development and manufacturer of sterile injectable pharmaceuticals and injectable-grade hyaluronic acid
- Deal type
- Platform
- Headquarters
- Chaska, Minnesota
Sources
- ir.lifecore.com
- JD SupraNov 5, 2026
Written by Buyout Desk from the sources above. Spotted an error? Email corrections@buyoutdesk.com.